Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
84.90
+1.14 (+1.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
46
47
Next >
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
September 27, 2022
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over.
Via
InvestorPlace
US Stock Futures Rise Ahead Of Economic Reports, Fed Speakers; Crude Oil Rises 1%
September 27, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade on Tuesday after recording losses on Monday. The Dow Jones fell into a bear market on Monday, while the S&P 500 recorded a...
Via
Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
September 26, 2022
Via
Benzinga
European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders
September 25, 2022
As the SPDR Portfolio Europe ETF (ARCA: SPEU) is down roughly 32% year-to-date, it may be a prime moment to hunt for stocks that have become undervalued in the European stock market. The SPDR Portfolio...
Via
Benzinga
3 Medical Stocks Displaying Remarkable Relative Strength In 2022
September 24, 2022
3 medical stocks that displayed a substantial amount of relative strength year-to-date.
Via
Talk Markets
AstraZeneca's Asthma Treatment Scores European Approval
September 21, 2022
Via
Benzinga
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
September 20, 2022
Via
Benzinga
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
September 23, 2022
Though successful in early testing, it wasn't enough to win a Phase 3 study.
Via
Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
Via
Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
Via
Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
Via
Benzinga
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
September 16, 2022
Via
Benzinga
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More...
September 13, 2022
Wall Street Journal
Via
Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
September 13, 2022
Via
Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
September 09, 2022
Via
Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
September 09, 2022
Via
Benzinga
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
September 06, 2022
Via
Benzinga
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
September 06, 2022
Via
Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
September 02, 2022
Via
Benzinga
Here's How Much $1000 Invested In AstraZeneca 5 Years Ago Would Be Worth Today
September 01, 2022
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 5.5% on an annualized basis producing an average annual return of 15.24%. Currently, AstraZeneca has a market...
Via
Benzinga
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
August 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
August 29, 2022
Upgrades
Via
Benzinga
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
August 29, 2022
Via
Benzinga
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
August 29, 2022
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress.
Via
Benzinga
Week In Review: China And The US May Settle De-Listing/Accounting Impasse
August 27, 2022
China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. The list of affected biopharma companies includes BeiGene, Legend Bio,...
Via
Talk Markets
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 25, 2022
Via
Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
August 25, 2022
Via
Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
August 24, 2022
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Via
Benzinga
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
August 23, 2022
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured...
Via
Benzinga
Amgen Touts Positive Data From Soliris-Based Biosimilar For Rare Blood Disorder
August 23, 2022
Via
Benzinga
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.